Clinical Trials Logo

Neurobehavioral Manifestations clinical trials

View clinical trials related to Neurobehavioral Manifestations.

Filter by:

NCT ID: NCT01493622 Completed - Schizophrenia Clinical Trials

The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia

Start date: June 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether minocycline are effective in the treatment of negative and cognitive symptoms in schizophrenia.

NCT ID: NCT01353196 Completed - Clinical trials for Cognitive Manifestations

Asymptomatic Carotid Stenosis: Cognitive Function and Plaque Correlates

ACCOF
Start date: May 15, 2011
Phase:
Study type: Observational

Carotid artery plaques are known to cause stroke. Cognitive impairment is an insidious but poorly understood problem in patients with carotid plaques. Cognitive function describes how people perform mental processes such as thinking, learning and problem solving. Asymptomatic carotid plaques may affect 1 million Veterans who may be at risk for cognitive impairment. In this study, the investigators will uncover the extent of cognitive impairment in Veterans with carotid stenosis who are currently labeled "asymptomatic". Programs to prevent or mitigate cognitive impairment will depend on identifying the mechanisms by which this occurs. The investigators will use sophisticated 3D imaging techniques developed by the group to measure the structure and composition of plaques, number of particles breaking off from them, blood levels of chemicals that could disrupt them, and blood flow restriction to the brain from them. This will help identify patients at risk for cognitive impairment who may benefit from preventative measures and improve selection of patients to decrease unnecessary surgical procedures.

NCT ID: NCT01333501 Completed - Multiple Sclerosis Clinical Trials

Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms

Cognition
Start date: May 2011
Phase: Phase 4
Study type: Interventional

The purpose of this pilot study is to evaluate, by means of a specific cognitive test battery (Brief Repeatable Battery and Delis-Kaplan Executive Function System scale), the slowing/reduction of cognitive dysfunction progression in RRMS patients after 18 months of treatment with fingolimod in comparison with interferon beta 1b treatment, and to evaluate which test of the battery is the most sensitive in detecting differences between treatment groups.

NCT ID: NCT01333215 Recruiting - Suicide, Attempted Clinical Trials

Study of Cognitive Inhibition Disorders in Depressed Older Suicide Attempters

ETIC
Start date: December 2010
Phase: N/A
Study type: Observational

The purpose of this study is to compare the cognitive inhibition deficit among depressed older suicide attempters compared to depressed older suicide non-attempters.

NCT ID: NCT01150071 Completed - Clinical trials for Lung Diseases, Obstructive

Growth, Health and Development in Children Born Extremely Preterm

PEP11
Start date: August 2010
Phase: N/A
Study type: Observational

Background: In a national Norwegian cohort of children born before 28 weeks gestation or with a birth weight less than 1000 g born in 1999 and 2000, 372 survived. Compared with earlier studies survival increased for the most immature infants, but at the cost of more early complications and a high rate of impairments, while the less immature children had fewer early complications and less impairments detectable within 5 years. These changes show the importance of monitoring outcome as treatment modalities change. Large brain haemorrhages were highly predictive of severe disabilities, but we have not found good predictive factors for milder impairments such as cognitive, behavioural and motor difficulties. However, at 5 years later function may be difficult to predict, and the children's potentials are better understood after completing several years in school. Objectives: The children will be re-examined at age 11 in order to assess their physical and mental health, and cognitive, motor and social function, and to determine if early life events and development at 2 and 5 years are predictive of long term health and functioning. MRI-studies, including functional MRI will be performed to examine if different outcomes related to brain function can be explained by differences in brain development. Methods: For all, data will be collected from the compulsory national test in 5th grade and questionnaires to the child, parents and teacher. For children in Western Norway (n=87) extensive examinations of lung and brain function, including clinical diagnostic tests and MRI, will be added. For all aspects of the study the investigators have appropriate current and historic reference populations for comparison. Implications: Knowledge on causes and of early predictions of outcome is needed to give appropriate advice to families, professionals and society, and to develop preventive programs.

NCT ID: NCT01138020 Active, not recruiting - Clinical trials for Traumatic Brain Injury

Cognitive Rehabilitation of Blast Traumatic Brain Injury (TBI)

CRbTBI
Start date: March 1, 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the efficacy of a structured rehabilitation program on cognitive function and quality of life in individuals with blast-induced traumatic brain injury (bTBI).

NCT ID: NCT01061242 Completed - Sleep Deprivation Clinical Trials

Intensive Care Unit (ICU) Sleep Quality and Neurocognitive Performance

Start date: January 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to understand patients' neurocognitive performance shortly after discharge from the Medical Intensive Care Unit (MICU) and the potential effect of sleep quality in the MICU on those neurocognitive outcomes. The investigators hypothesize that post-ICU neurocognitive function and patient overall ICU sleep experience will improve through a pre-existing MICU sleep improvement initiative.

NCT ID: NCT00733057 Completed - Clinical trials for Negative and Cognitive Symptoms in Schizophrenia

Minocycline for the Treatment of Early-Phase Schizophrenia

Start date: August 2003
Phase: Phase 3
Study type: Interventional

Current antipsychotics have only a limited effect on two core symptoms of schizophrenia, negative symptoms and cognitive deficits. Minocycline is a second-generation tetracycline which has a beneficial effect in various neurological disorders. Recent findings in animal models and human case-reports suggest its potential for the treatment of these symptoms of schizophrenia. The current study aims to examine the efficacy of minocycline as add-on treatment for alleviating negative and cognitive symptoms in early-phase schizophrenia. The study will utilize a longitudinal double blind, randomized, placebo-controlled design with patients followed for six-months. Early-phase schizophrenia patients were recruited and randomly allocated to a minocycline or placebo treatment (2:1 ratio; 200 mg/day). The primary outcome measures are the Scale for Assessment of Negative Symptoms (SANS) and assessments of executive functions.

NCT ID: NCT00586638 Completed - Clinical trials for Neurologic Manifestations

Training Cognitive Control Processes in Older Adults

Start date: December 2007
Phase: N/A
Study type: Interventional

Control processes are classes of brain activity that initiate, coordinate, synchronize, and regulate elemental cognitive functions for the conduct of goal-directed behavior. The proposed research investigates whether exposure to a computer-based training protocol designed to enhance cognitive control processes will improve cognitive performance in healthy older adults.

NCT ID: NCT00560937 Completed - Schizophrenia Clinical Trials

Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia

Start date: June 2005
Phase: N/A
Study type: Interventional

This is a pilot study of pregnenolone as an augmentation treatment for schizophrenia. The goal of this placebo-controlled study is to provide preliminary efficacy data for potential pregnenolone effects on cognitive symptoms and negative symptoms in patients with schizophrenia. Depressive symptoms and positive symptoms will also be assessed.